Literature DB >> 22509912

Model IgG monoclonal autoantibody-anti-idiotype pair for dissecting the humoral immune response to oxidized low density lipoprotein.

Shang-Hung Chang1, Michael Johns, Joseph J Boyle, Ellen McConnell, Paul A Kirkham, Colin Bicknell, M Zahoor-ul-Hassan Dogar, Robert J Edwards, Oliver Gale-Grant, Ramzi Khamis, Kurrun V V Ramkhelawon, Dorian O Haskard.   

Abstract

Increasing evidence implicates IgG autoantibodies against oxidized forms of low density lipoprotein (oxLDL) in the pathophysiology of atherosclerotic arterial disease. However, insufficient knowledge of their structure and function is a key gap. Using an elderly LDL receptor-deficient atherosclerotic mouse, we isolated a novel IgG3k against oxLDL (designated MAb LO1). LO1 reacts with copper-oxidized LDL, but minimally with native LDL. Further analysis showed that MAb LO1 also reacts in vitro with malondialdehyde-conjugated LDL (MDA-LDL), a known key epitope in copper-oxidized LDL preparations. By screening a phage library expressing single chain variable region antibodies (scFv), we selected an anti-idiotype scFv (designated H3) that neutralizes MAb LO1 binding to MDA-LDL. Amino acid substitutions between H3 and an irrelevant control scFv C12 showed that residues in the H3 CDRH2, CDRH3, and CDRL2 are all critical for MAb LO1 binding, consistent with a conformational epitope on H3 involving both heavy and light chains. Comparison of amino acids in H3 CDRH2 and CDRL2 with apoB, the major LDL protein, showed homologous sequences, suggesting H3 has structural similarities to the MAb LO1 binding site on MDA-LDL. Immunocytochemical staining showed that MAb LO1 binds epitopes in mouse and human atherosclerotic lesions. The MAb LO1-H3 combination therefore provides a very promising model for analyzing the structure and function of an individual IgG autoantibody in relation to atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22509912      PMCID: PMC3326269          DOI: 10.1089/hyb.2011.0058

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  55 in total

1.  Antibody arrays for high-throughput screening of antibody-antigen interactions.

Authors:  R M de Wildt; C R Mundy; B D Gorick; I M Tomlinson
Journal:  Nat Biotechnol       Date:  2000-09       Impact factor: 54.908

2.  Binding of an antibody mimetic of the human low density lipoprotein receptor to apolipoprotein E is governed through electrostatic forces. Studies using site-directed mutagenesis and molecular modeling.

Authors:  R Raffaï; K H Weisgraber; R MacKenzie; B Rupp; E Rassart; T Hirama; T L Innerarity; R Milne
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

3.  Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3' to 5' exonuclease activity.

Authors:  Z Wang; M Raifu; M Howard; L Smith; D Hansen; R Goldsby; D Ratner
Journal:  J Immunol Methods       Date:  2000-01-13       Impact factor: 2.303

4.  Transport of large molecules from plasma to interstitial fluid and lymph in dogs.

Authors:  D G Garlick; E M Renkin
Journal:  Am J Physiol       Date:  1970-12

5.  Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo.

Authors:  P X Shaw; S Hörkkö; S Tsimikas; M K Chang; W Palinski; G J Silverman; P P Chen; J L Witztum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-08       Impact factor: 8.311

Review 6.  Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity.

Authors:  Yury I Miller; Soo-Ho Choi; Philipp Wiesner; Longhou Fang; Richard Harkewicz; Karsten Hartvigsen; Agnès Boullier; Ayelet Gonen; Cody J Diehl; Xuchu Que; Erica Montano; Peter X Shaw; Sotirios Tsimikas; Christoph J Binder; Joseph L Witztum
Journal:  Circ Res       Date:  2011-01-21       Impact factor: 17.367

7.  Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease.

Authors:  Gunilla Nordin Fredrikson; Bo Hedblad; Göran Berglund; Ragnar Alm; Mikko Ares; Bojan Cercek; Kuang-Yuh Chyu; Prediman K Shah; Jan Nilsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-20       Impact factor: 8.311

8.  Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis.

Authors:  Alexandru Schiopu; Jenny Bengtsson; Ingrid Söderberg; Sabina Janciauskiene; Stefan Lindgren; Mikko P S Ares; Prediman K Shah; Roland Carlsson; Jan Nilsson; Gunilla Nordin Fredrikson
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

9.  Activation of mouse complement by monoclonal mouse antibodies.

Authors:  M S Neuberger; K Rajewsky
Journal:  Eur J Immunol       Date:  1981-12       Impact factor: 5.532

10.  Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody.

Authors:  Samareh Azeredo da Silveira; Shuichi Kikuchi; Liliane Fossati-Jimack; Thomas Moll; Takashi Saito; J Sjef Verbeek; Marina Botto; Mark J Walport; Michael Carroll; Shozo Izui
Journal:  J Exp Med       Date:  2002-03-18       Impact factor: 14.307

View more
  8 in total

1.  Near Infrared Fluorescence (NIRF) Molecular Imaging of Oxidized LDL with an Autoantibody in Experimental Atherosclerosis.

Authors:  Ramzi Y Khamis; Kevin J Woollard; Gareth D Hyde; Joseph J Boyle; Colin Bicknell; Shang-Hung Chang; Talat H Malik; Tetsuya Hara; Adam Mauskapf; David W Granger; Jason L Johnson; Vasilis Ntziachristos; Paul M Matthews; Farouc A Jaffer; Dorian O Haskard
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

2.  Developing a Strategy for Interventional Molecular Imaging of Oxidized Low-Density Lipoprotein in Atherosclerosis.

Authors:  Samata S Pandey; Dorian O Haskard; Ramzi Y Khamis
Journal:  Mol Imaging       Date:  2017 Jan-Dec       Impact factor: 4.488

3.  IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3).

Authors:  Victor J van den Berg; Dorian O Haskard; Artur Fedorowski; Adam Hartley; Isabella Kardys; Mikhail Caga-Anan; K Martijn Akkerhuis; Rohit M Oemrawsingh; Robert Jan van Geuns; Peter de Jaegere; Nicolas van Mieghem; Evelyn Regar; Jurgen M R Ligthart; Victor A W M Umans; Patrick W Serruys; Olle Melander; Eric Boersma; Ramzi Y Khamis
Journal:  EBioMedicine       Date:  2018-08-18       Impact factor: 8.143

4.  Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a).

Authors:  Tina Z Khan; Adam Hartley; Dorian Haskard; Mikhail Caga-Anan; Dudley J Pennell; Peter Collins; Mahmoud Barbir; Ramzi Khamis
Journal:  Antioxidants (Basel)       Date:  2021-01-18

Review 5.  Intravascular Molecular Imaging: Near-Infrared Fluorescence as a New Frontier.

Authors:  Haitham Khraishah; Farouc A Jaffer
Journal:  Front Cardiovasc Med       Date:  2020-11-23

6.  A Novel Immunoassay for Malondialdehyde-Conjugated Low-Density Lipoprotein Measures Dynamic Changes in the Blood of Patients Undergoing Coronary Artery Bypass Graft Surgery.

Authors:  Samata S Pandey; Adam Hartley; Mikhail Caga-Anan; Tareq Ammari; Ameer Hamid Ahmed Khan; Bao Anh Vu Nguyen; Chiari Kojima; Jon Anderson; Steven Lynham; Michael Johns; Dorian O Haskard; Ramzi Y Khamis
Journal:  Antioxidants (Basel)       Date:  2021-08-17

7.  The Placebo-Controlled Effect of Percutaneous Coronary Intervention on Exercise Induced Changes in Anti-Malondialdehyde-LDL Antibody Levels in Stable Coronary Artery Disease: A Substudy of the ORBITA Trial.

Authors:  Adam Hartley; Matthew Shun-Shin; Mikhail Caga-Anan; Christopher Rajkumar; Alexandra N Nowbar; Michael Foley; Darrel P Francis; Dorian O Haskard; Ramzi Y Khamis; Rasha K Al-Lamee
Journal:  Front Cardiovasc Med       Date:  2021-10-11

8.  High Serum Immunoglobulin G and M Levels Predict Freedom From Adverse Cardiovascular Events in Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.

Authors:  Ramzi Y Khamis; Alun D Hughes; Mikhail Caga-Anan; Choon L Chang; Joseph J Boyle; Chiari Kojima; Paul Welsh; Naveed Sattar; Michael Johns; Peter Sever; Jamil Mayet; Dorian O Haskard
Journal:  EBioMedicine       Date:  2016-06-20       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.